- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | H.C. Wainwright cuts Evommune stock price target on dilution | 3 | Investing.com | ||
| Mi | This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | 1 | Benzinga.com | ||
| 17.03. | Clear Street initiates Evommune stock with buy rating on drug potential | 1 | Investing.com | ||
| 12.03. | Leerink reiterates Evommune stock rating after conference chat | 1 | Investing.com | ||
| EVOMMUNE Aktie jetzt für 0€ handeln | |||||
| 11.03. | Evommune: RBC Capital startet Coverage mit "Outperform" und sieht 100 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 11.03. | RBC Capital initiates Evommune stock with outperform rating | 1 | Investing.com | ||
| 06.03. | Evommune, Inc Loss At -$28.27 Mln In Q4 | - | RTTNews | ||
| 06.03. | Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M | 1 | Seeking Alpha | ||
| 05.03. | Evommune, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 05.03. | Evommune, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Evommune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.02. | Evommune beschafft 125 Millionen US-Dollar über Privatplatzierung für Forschung und Entwicklung | 2 | Investing.com Deutsch | ||
| 13.02. | Evommune raises $125 million in private placement to fund R&D | 1 | Investing.com | ||
| 13.02. | Evommune raises $125M privately | 1 | Seeking Alpha | ||
| 12.02. | Evommune Stock Cools Off After Big Rally On Successful Eczema Trial | 2 | Benzinga.com | ||
| 11.02. | Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill | 7 | BioPharma Dive | ||
| 10.02. | Evommune Starts Making Case to Challenge Dominance of Sanofi's Dupixent in Atopic Dermatitis | 27 | MedCity News | ||
| 10.02. | Evommune: Evercore ISI hebt Kursziel nach positiven Studiendaten auf 55 US-Dollar an | 15 | Investing.com Deutsch | ||
| 10.02. | Evommune stock price target raised to $55 by Evercore ISI on positive trial data | 1 | Investing.com | ||
| 10.02. | Evommune's Stock Surges On Strong Results For New Eczema Drug | 1 | Benzinga.com |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 4,750 | 0,00 % | What's Going On With bioAffinity Stock Thursday? | ||
| APOGEE THERAPEUTICS | 79,16 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 34,130 | -0,34 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| CG ONCOLOGY | 64,92 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,750 | 0,00 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen | |
| ERASCA | 14,310 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| ARCELLX | 114,61 | 0,00 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,570 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| PRAXIS PRECISION MEDICINES | 293,87 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| TYRA BIOSCIENCES | 36,500 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| BIONTECH | 75,00 | -2,72 % | DEUTSCHE BANK RESEARCH stuft Biontech auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Biontech mit einem Kursziel von 140 US-Dollar auf "Buy" belassen. Der Antikörperspezialist habe einen etwas verwirrenden... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,400 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| VALNEVA | 2,926 | -35,27 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 49,080 | 0,00 % | Citizens reiterates Structure Therapeutics stock rating on weight loss data | ||
| ALUMIS | 23,370 | 0,00 % | Alumis Inc.: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements | - Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis... ► Artikel lesen |
EVOMMUNE INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 23,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOMMUNE INC finden Sie auf Wallstreet Online.